证券代码：430478 证券简称：峆一药业 公告编号：2025-032 2024 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 本人杨模荣作为安徽峆一药业股份有限公司（以下简称"公司"）的独立 董事，在任职期间严格按照《公司法》《证券法》《公司章程》《北京证券交 易所股票上市规则（试行）》《北京证券交易所上市公司持续监管指引第1号— —独立董事》《上市公司独立董事管理办法》等法律法规的规定和要求，谨慎、 认真、勤勉、独立地履行职责，持续关注公司规范运作、重大生产经营活动、财 务状况等，积极出席 2024年度的相关会议，认真审议各项议案，对重大事项发 表了独立意见，维护了公司整体利益和全体股东尤其是中小股东的合法权益。现 就2024年度任职期间内履行职责情况汇报如下： 一、独立董事独立性情况 作为公司的独立董事，本人及本人直系亲属均不在公司或其附属企业担任 除独立董事之外的其他职务，也未在公司主要股东处担任任何职务；没有为公 司或其附属企业提供财务、法律、咨询等服务。除独立董事津贴外，没有从公 司及其主 ...

证券代码：430478 证券简称：峆一药业 公告编号：2025-031 2024 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 本人冯乙巳作为安徽峆一药业股份有限公司（以下简称"公司"）的独立 董事，在任职期间严格按照《公司法》《证券法》《公司章程》《北京证券交 易所股票上市规则（试行）》《北京证券交易所上市公司持续监管指引第1号— —独立董事》《上市公司独立董事管理办法》等法律法规的规定和要求，谨慎、 认真、勤勉、独立地履行职责，持续关注公司规范运作、重大生产经营活动、财 务状况等，积极出席 2024年度的相关会议，认真审议各项议案，对重大事项发 表了独立意见，维护了公司整体利益和全体股东尤其是中小股东的合法权益。现 就 2024年度任职期间内履行职责情况汇报如下： 一、独立董事独立性情况 作为公司的独立董事，本人及本人直系亲属均不在公司或其附属企业担任 除独立董事之外的其他职务，也未在公司主要股东处担任任何职务；没有为公 司或其附属企业提供财务、法律、咨询等服务。除独立董事津贴外，没有从公 司及其 ...

Share Repurchase and Equity Incentive - The company repurchased 514,900 shares, accounting for 0.9159% of the total share capital, for the purpose of an equity incentive plan[7]. - The 2024 equity incentive plan was approved, granting 514,900 restricted stocks at a price of 9.10 RMB per share to 37 individuals[9]. - The total amount paid for the share repurchase reached 6,001,548.78 CNY, accounting for 60.02% of the planned repurchase budget[132]. - The share repurchase plan aims to buy back between 375,000 and 625,000 shares, representing 0.67% to 1.11% of the total share capital[130]. - The company completed the 2024 equity incentive plan, granting 514,900 restricted shares at a price of 9.10 CNY per share[129]. Financial Performance - The company's operating revenue for 2024 reached ¥270,466,229.84, representing a year-over-year increase of 19.54% compared to ¥226,253,170.32 in 2023[28]. - The net profit attributable to shareholders for 2024 was ¥49,664,051.16, a 2.25% increase from ¥48,572,460.01 in 2023[28]. - The net profit after deducting non-recurring gains and losses increased by 35.18% to ¥45,245,491.34 in 2024 from ¥33,470,776.11 in 2023[28]. - Total assets at the end of 2024 amounted to ¥561,586,391.04, reflecting a growth of 5.29% from ¥533,395,393.75 in 2023[29]. - The company's total liabilities slightly decreased by 0.22% to ¥66,072,077.85 in 2024 from ¥66,215,014.88 in 2023[29]. - The weighted average return on equity based on net profit attributable to shareholders was 10.54% in 2024, down from 11.62% in 2023[28]. - The basic earnings per share for 2024 was ¥0.89, a decrease of 2.20% compared to ¥0.91 in 2023[28]. - The operating cash flow for 2024 was ¥41,462,010.43, showing a slight increase of 0.04% from ¥41,446,334.08 in 2023[29]. - The company's inventory turnover ratio improved to 1.89 in 2024 from 1.82 in 2023[30]. - The company's main business income increased by 20.20% to ¥269,420,880.33, compared to ¥224,150,865.51 in the previous year[68]. Research and Development - The company obtained several invention patents, including a low-impurity content synthesis method for vortioxetine and a preparation method for 4-amino-2,6-dichloropyridine[8]. - The company is recognized as a national high-tech enterprise, holding 13 invention patents and 19 utility model patents, indicating strong R&D capabilities[40]. - The company's R&D expenses grew by 29.69% to ¥20,513,979.77, reflecting increased investment in personnel and materials[67]. - The company has completed several R&D projects, including the optimization of production processes for various pharmaceutical intermediates, which are expected to enhance product quality and reduce costs[98][99]. - The company emphasizes technology innovation by increasing investment in R&D resources and closely monitoring industry trends to enhance product performance and functionality[117]. Market and Business Strategy - The company focuses on the research and sales of advanced pharmaceutical intermediates and raw materials[22]. - The company operates in the pharmaceutical manufacturing industry, specifically in the production of chemical drug raw materials[22]. - The company maintains a stable long-term cooperation with downstream clients, including well-known pharmaceutical companies in South Korea and Japan[40]. - The company’s business model remains unchanged, focusing on the R&D, production, and sales of high-end pharmaceutical intermediates and APIs[48]. - The company plans to expand its market presence through strategic investments and new product development initiatives[92]. Compliance and Governance - The company has a commitment to maintaining the accuracy and completeness of its financial reporting, as confirmed by its management[13]. - The company has no significant litigation or arbitration matters during the reporting period[127]. - There are no instances of shareholders or related parties occupying or transferring company funds or assets[127]. - The company has committed to avoid competition with its controlling shareholders and related parties[134]. - The company will ensure that all related transactions are conducted in accordance with market principles to protect the interests of all shareholders[156]. Shareholder and Management Information - The company has a total of 9 board members and 3 supervisors, with 4 senior management personnel[184]. - The total remuneration paid to directors, supervisors, and senior management during the reporting period amounted to CNY 2.9944 million[193]. - The company has a total of 29,131,485 shares held by directors, accounting for 51.82% of total shares[186]. - The company’s independent directors have not changed during the reporting period[189]. - The company’s major shareholders agreed that any profits from violations of commitments would be returned to the company, and they would not transfer their shares until the violations are rectified[162]. Employee and Workforce Development - The total number of employees increased from 424 to 439, with a net addition of 19 employees during the reporting period[197]. - The number of technical personnel rose from 76 to 91, reflecting a growth of 19.74%[197]. - The company has implemented a comprehensive employee training program to enhance professional skills and management levels[199]. - The company maintains a full labor contract system for all employees, ensuring compliance with social insurance and tax regulations[199]. - The number of employees with a doctoral degree increased from 2 to 4, representing a 100% increase[198].

一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.8900 | 0.9100 | -2.2 | 1.8800 | | 每股净资产（元） | 8.61 | 11.35 | -24.14 | 10.29 | | 每股公积金(元) | 2.09 | 3.34 | -37.43 | 1.14 | | 每股未分配利润(元) | 5.19 | 6.53 | -20.52 | 7.65 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 2.7 | 2.26 | 19.47 | 2.59 | | 净利润(亿元) | 0.5 | 0.49 | 2.04 | 0.57 | | 净资产收益率(%) | 10.54 | 11.62 | -9.29 | 19.83 | 前十大流通股东累计持有： 870.56万股，累计占流通股比： 25.83%，较上期变化： -23.36万股。 | 名称 持有数量(万股) | | 占总 ...

Investment Rating - The report assigns an "Accumulate" rating for the company for the first time [1]. Core Views - The company, Fangyi Pharmaceutical, focuses on high-value-added areas such as anti-allergy, anti-thrombotic, and antioxidant products, with a significant portion of its revenue coming from overseas markets [5][11]. - The company has established a CDMO (Contract Development and Manufacturing Organization) business, which is expected to drive future growth alongside its core pharmaceutical products [5][27]. - The financial forecast indicates steady revenue and profit growth, with projected revenues of 270.46 million, 324.56 million, and 398.62 million yuan for 2024, 2025, and 2026 respectively, reflecting growth rates of 19.54%, 20.00%, and 22.82% [4][5]. Summary by Sections Company Overview - Fangyi Pharmaceutical was founded in 2007 and is a leading domestic enterprise in specialty APIs and pharmaceutical intermediates, focusing on high-value areas [5][11]. - The company has a high concentration of ownership, with the largest shareholder, Dong Laishan, holding 39.20% of the shares, which enhances decision-making efficiency [1][5]. Product and Business Layout - The company specializes in high-end pharmaceutical intermediates and APIs, with products used in various therapeutic areas including anti-allergy and anti-thrombotic [27][28]. - The CDMO business, initiated in 2021, is showing promising results and is expected to become a new growth engine for the company [27][28]. Financial Performance - The company reported total revenue of 258.70 million yuan in 2022, with a projected increase to 270.46 million yuan in 2024, representing a growth rate of 19.54% [4][5]. - The net profit attributable to shareholders is expected to grow from 49.63 million yuan in 2024 to 74.74 million yuan in 2026, with growth rates of 2.17% and 22.11% respectively [4][5]. Industry Analysis - The global pharmaceutical market is projected to exceed 1.9 trillion USD by 2027, with China being a leading consumer market, driven by aging population and trends in innovative drug outsourcing [5][11]. - The CDMO market is expected to expand significantly, providing opportunities for companies with technological advantages and international presence [5][11].

证券代码：430478 证券简称：峆一药业 公告编号：2025-018 安徽峆一药业股份有限公司 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 安徽峆一药业股份有限公司（以下简称"公司 "）于2024年4月10日召开了 第四届董事会第十五次会议，审议通过了《关于聘请公司2024年度审计机构的议 案》，同意聘请容诚会计师事务所（特殊普通合伙）（以下简称"容诚"）为公 司2024年度审计机构，聘期1年。具体内容详见公司于2024年4月11日披露的《续 聘2024年度会计师事务所公告》（公告编号：2024-013）。 签字注册会计师：周文亮先生，2014年成为中国注册会计师，2008年开始 从事上市公司审计业务，2008年开始在容诚执业，2023年开始为公司提供审计服 务；近三年签署过斯迪克（300806.SZ）、英力股份（300956.SZ）、五洲医疗（ 301234.SZ）等上市公司审计报告。 签字注册会计师：吴玉娣女士，2017年成为中国注册会计师，2011年开始 从事上市公司审计业务，2011年开始 ...

法律意见书 地址：上海市徐汇区宜山路 425 号光启城 24 层 电话：021-60328686 邮编：200030 上海德禾翰通律师事务所 法律意见书 上海德禾翰通律师事务所 关于安徽峆一药业股份有限公司 2025 年第一次临时股东大会的 上海德禾翰通律师事务所 关于安徽峆一药业股份有限公司 2025 年第一次临时股东大会的 法律意见书 致：安徽峆一药业股份有限公司 上海德禾翰通律师事务所（以下简称"本所"）接受安徽峆一药业股份有限 公司（以下简称"公司"）委托，就公司召开 2025 年第一次临时股东大会（以下 简称"本次股东大会"、"本次会议"）的有关事宜，根据《中华人民共和国公司 法》（以下简称"《公司法》"）、《上市公司股东大会规则》等法律、法规、规章和 其他规范性文件以及《安徽峆一药业股份有限公司章程》（以下简称"《公司章程》"） 的有关规定，出具本法律意见书。 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定，严格履行 了法定职责，遵循了勤勉尽责和诚实信用原则，对本次股东大会所涉及的相关事 项进行了必要的核查和验证，核 ...

证券代码：430478 证券简称：峆一药业 公告编号：2025-017 本次保荐代表人更换后，公司持续督导保荐代表人变更为蒋顾鑫先生、涂 士华先生。本次变更持续督导保荐代表人的事项不会对公司的经营活动造成任 何风险和影响。公司董事会对胡永舜先生担任公司保荐代表人期间所做的工作 表示衷心感谢！ 安徽峆一药业股份有限公司 董事会 2025 年 3 月 21 日 附件：涂士华先生简历： 涂士华，保荐代表人，注册会计师，管理学硕士。安徽峆一药业股份有限 公司向不特定合格投资者公开发行股票并上市项目协办人。作为项目组成员参 与皖维高新发行股份购买资产并募集配套资金项目、安徽交欣科技股份有限公 司新三板挂牌项目、合肥东芯通信股份有限公司股票定向发行项目、安徽永锋 防护科技股份有限公司股票定向发行等项目，参与了多家拟上市公司的尽职调 查和改制工作。 安徽峆一药业股份有限公司 关于变更持续督导保荐代表人的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 安徽峆一药业股份有限公司（以下简称"公司"）于近日收到国元证券 ...

证券代码：430478 证券简称：峆一药业 公告编号：2025-015 安徽峆一药业股份有限公司 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 3 月 21 日 2.会议召开地点：公司一楼会议室 3.会议召开方式：本次会议采用现场投票和网络投票相结合方式召开。 4.会议召集人：本次股东大会的召集人为董事会。 5.会议主持人：董事长董来山先生 审议通过《关于变更募集资金用途的议案》 6.召开情况合法、合规、合章程性说明： 本次会议的召集、召开、议案审议程序符合有关法律、行政法规、部门规章、 规范性文件和《公司章程》的规定。 （二）会议出席情况 出席和授权出席本次股东大会的股东共 8 人，持有表决权的股份总数 29,131,485 股，占公司有表决权股份总数的 51.8166%。 其中通过网络投票参与本次股东大会的股东共 0 人，持有表决权的股份总数 0 股，占公司有表决权股份总数的 0%。 ...

国元证券股份有限公司（以下简称"保荐机构"或"国元证券"）作为安徽峆一 药业股份有限公司（以下简称"峆一药业"或"公司"）的保荐机构，根据《证券发 行上市保荐业务管理办法》《北京证券交易所上市公司持续监管办法（试行）》《北 京证券交易所证券发行上市保荐业务管理细则》《北京证券交易所股票上市规则 （试行）》等有关规定，对峆一药业为控股子公司提供担保事项进行核查，核查 意见如下： 一、本次担保的具体情况 为满足经营和发展需要，公司控股子公司安徽峆一达善医药有限公司拟向银 行等金融机构申请不超过 2 亿元人民币固定资产贷款，期限不超过 8 年。公司拟 为控股子公司安徽峆一达善医药有限公司提供连带责任保证担保，该笔担保占公 司最近一期经审计的净资产 455,799,065.23 元的比例为 43.88%。 二、担保协议的主要内容 国元证券股份有限公司 关于安徽峆一药业股份有限公司 为控股子公司提供担保的核查意见 公司本次为控股子公司提供担保事项的信息披露真实、准确、完整，符合《北 京证券交易所证券发行上市保荐业务管理细则》《北京证券交易所股票上市规则 （试行）》等相关法律法规的要求，不存在损害股东利益的情况。公司为控 ...